“The Insider by DFIN” is a series of video interviews featuring latest topics and key perspectives on the global capital markets.
It has been said that we are at the front end of an explosion of science--and that this is "the century" of biology. There is no question or doubt that the COVID-19 pandemic accelerated the Life Sciences industry—and that speed of innovation is nothing short of remarkable and unparalleled.
To put it bluntly: with four vaccines in less than two years, Life Sciences and those that helped to lead the global response, helped to save the world. Life Sciences continues amaze, treat, mitigate, revive, and innovate. . .again and again.
In 2020 alone, there were thirteen biotech companies that went public, and in 2021, that number truly soared. In August, there were 243 Life Science deals—and the year is not over yet.
For private Life Sciences organizations that are seeking to go public, it is important to make note of key considerations as you embark on your journey. Especially now that everyone—within the financial world and otherwise—knows, admires, and appreciates what you do. It does not matter whether you decide to go the traditional route or via a SPAC, what does matter is if you are aligned with the right team, the right partner, and the right financial management tools and solutions to help you along the way. Making these key and necessary decisions is what you need to do to be successful now and in the future.
As the demand for new therapeutics and treatments for both acute and chronic disease continues to increase, there is no doubt that as we look toward 2022, the Life Sciences market will continue to be in high demand. And for that, I am incredibly humble, privileged, and thankful to play a part in it.
